Dr. Bradley Monk MD, FACS, FACOG

Dr. Bradley Monk graduated at the top of his class from the University of Arizona College of Medicine-Tucson in 1988 and completed a residency in Obstetrics and Gynecology at the University of California, Los Angeles, in 1992. In 1995, he completed his fellowships in Gynecologic Oncology at the University of California, Irvine. In 1995, Dr. Monk was appointed Director of Gynecologic Oncology at Texas Tech University Health Services Center and, from 1998 until 2010, was Associate Professor with Tenure in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center and Director of Research in the Department of Obstetrics and Gynecology. After moving to Arizona, Dr. Monk was appointed Director and Professor in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ in 2010. Dr. Monk also became a Professor on the Clinical Scholar Track at the University of Arizona College of Medicine, Phoenix. In 2016, he transitioned of Arizona Oncology and part of the US Oncology Network. He was chair of the Gynecologic Cancer Committee for US Oncology Research until 2022 when his practice was acquired by HonorHealth. He began serving as Director and Principal Investigator working at the Virginia G. Piper Cancer Center at HonorHealth where he was also the Site Research Leader for Sarah Cannon Research Institute. In January 2024, he moved to West Palm Beach Florida and joined Florida Cancer Specialists and Research Institute. He was appointed the Medical Director of the Late-Phase Clinical Research Program across the state network and is accountable for all cancer types. Dr. Monk’s research interests include the prevention and treatment of gynecologic cancers. He was the first to report the activity of anti-vascular growth factor (VEGF) therapy in ovarian and cervical cancers and his papers in the New England Journal of Medicine led to the global approval of anti-VEGF therapy in recurrent cervical cancer in 2014 and advanced ovarian in 2018. He was also the lead author on the pivotal trial of trabectedin in recurrent ovarian cancer as well as many other studies that have met their primary endpoints. Additionally, his other papers in the New England Journal of Medicine, Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology have led to multiple FDA/EMA approvals of PARP inhibitors, cytotoxics, and immunotherapy in advanced and recurrent ovarian, cervical and endometrial cancer. Dr. Monk was also awarded the highly prestigious Ernst Wertheim Award for his research in cervical cancer in Salzburg Austria. He was the Cervical Cancer Sub-Committee Chair for NRG Oncology for 11 years and is a prior Chair of the Cervical Cancer Committee for the Gynecologic Cancer Intergroup. Dr. Monk is a fellow of the American College of Surgeons, the American College of Obstetricians and Gynecologists (board certified) and the American Society for Colposcopy and Cervical Pathology, as well as being an active member of the Society of Gynecologic Oncology, International Gynecologic Cancer Society and American Society of Clinical Oncology. He has authored more than 450 peer-reviewed articles along with more than 35 book chapters dealing predominantly with the prevention and treatment of gynecologic malignancies and patient reported outcomes. He is on the editorial board for multiple peer-review oncology journals and is the gynecologic cancer section co-editor for Annals of Oncology (official journal of the European Society of Medical Oncology. Finally, he is Vice President and on the Board of Directors for the GOG-Foundation and directs the GOG-Partners Research consortium which he co-founded in 2010.